RxDoctor Payments Data

Julie Heimbach, MD

Transplant Surgery · Rochester, MNNPI 1225016025

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Genentech USA, Inc. at 44.4% of the total. Reporting peaked in 2023 at $6,944 and has fallen 94.1% since, to $408 in 2025.

$7,427in general payments, 2019–2025

Across 15 payments — averaging $495.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$3K
  • Intuitive Surgical$2K
  • Transmedics, Inc.$2K
  • Xvivo Perfusion Inc.$353
  • Dilon Technologies, Inc.$76
$121,098in research payments, 2019–2025

Across 8 payments — averaging $15,137 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Transmedics, Inc.$121K

What the payments were for

  • Consulting fees$3,16543%
  • Travel & lodging$2,05828%
  • Food & beverage$6509%
  • Education$1,55421%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,427 in reported general payments places this provider in the 80th percentile of 21 transplant surgery providers in Minnesota.

See all transplant surgery providers in Minnesota

Medicare billing

Part B allowed, 2024
$91,848
Medicare patients
34
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other transplant surgery in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →